LoveThemStocks
17 horas hace
Amprius Technologies, Inc.'s (NYSE:AMPX) market cap surged US$55m last week, retail investors who have a lot riding on the company were rewarded
To get a sense of who is truly in control of Amprius Technologies, Inc. (NYSE:AMPX), it is important to understand the ownership structure of the business. We can see that retail investors own the lion's share in the company with 60% ownership. That is, the group stands to benefit the most if the stock rises (or lose the most if there is a downturn).
Clearly, retail investors benefitted the most after the company's market cap rose by US$55m last week.
What Does The Institutional Ownership Tell Us About Amprius Technologies?
Institutional investors commonly compare their own returns to the returns of a commonly followed index. So they generally do consider buying larger companies that are included in the relevant benchmark index.
We can see that Amprius Technologies does have institutional investors; and they hold a good portion of the company's stock. This implies the analysts working for those institutions have looked at the stock and they like it. But just like anyone else, they could be wrong. If multiple institutions change their view on a stock at the same time, you could see the share price drop fast. It's therefore worth looking at Amprius Technologies' earnings history below. Of course, the future is what really matters.
LoveThemStocks
5 días hace
Amprius jumps as Northland more than doubles target, names a 2025 top pick
Northland analyst Ted Jackson raised the firm’s price target on Amprius Technologies (AMPX) to $10 from $4 and keeps an Outperform rating on the shares, which the analyst is designating as a “2025 top pick.” The firm expects full-year 2024 revenue of $21.2M and forecasts FY25 total sales to grow 285% to $81.8M, notes the analyst, who calls Amprius “a high-risk-high-reward play on battery technology.” Amprius shares are up $1.03, or 34%, to $4.06 in Friday morning trading.
https://finance.yahoo.com/news/amprius-jumps-northland-more-doubles-154545643.html
TradingCharts
5 días hace
Amprius Technologies to Present at the 27th Annual Needham Growth Conference
https://batteriesnews.com/amprius-technologies-to-present-at-the-27th-annual-needham-growth-conference/
FREMONT, Calif.–(BUSINESS WIRE)–Amprius Technologies, Inc. (“Amprius” or the “Company”) (NYSE: AMPX), a leader in next-generation lithium-ion batteries with its Silicon Anode Platform, today announced that it will participate in the 27th Annual Needham Growth Conference on Tuesday, January 14, 2025.
The management team is scheduled to present at 9:30 a.m. Eastern time. The presentation will be available live and for replay here.
TradingCharts
2 semanas hace
Kieran O'Regan
Co-Founder & CGO of About:Energy
https://www.linkedin.com/posts/kieranoregan1994_which-amprius-technologies-inc-cells-activity-7282365323029147649-HH6m?utm_source=share&utm_medium=member_desktop
✨ Which Amprius Technologies, Inc. cells are the most popular and why?
Amprius, a developer of high-energy-density cells, uses advanced silicon anode technology in its batteries. With 14 cells across their SiCore and SiMaxx ranges, selecting the right one can be challenging but is critical for optimizing cost, performance, and sustainability in any battery program.
Here are 4 of the most popular Amprius cells in the SiCore range:
• Amprius SA10: 300 Wh/kg & 1042 W/kg – A 18650 cylindrical cell for easy upgrades from legacy technologies.
• Amprius SA17: 300 Wh/kg & 1013 W/kg – Another cylindrical cell, but is 21700.
• Amprius SA08: 360 Wh/kg & 2028 W/kg – The highest power pouch cell in their lineup.
• Amprius SA03: 400 Wh/kg & 853 W/kg – The highest energy pouch cell, ideal for applications demanding peak energy density.
While pouch cells deliver the highest metrics, their development often requires more investment in testing, system engineering, and pack safety design. On the other hand, cylindrical cells offer simpler integration for faster adoption.
🚀 Thinking about using Amprius cells in your 2025+ programs in space, aviation, or e-mobility? At About:Energy, we’re building predictive models to accelerate their use and unlock their potential for next-gen products. Let’s chat!
TradingCharts
2 semanas hace
Amprius is proud to be one of the battery providers supporting KULR Technology Group, Inc (NYSE: KULR) in their K1S rideshare mission launching with Exolaunch and SpaceX in 2026!
This pathfinder mission will integrate multiple configurations of the hashtag#KULR ONE Space (K1S) battery into a lightweight satellite, showcasing the first commercial-off-the-shelf (COTS) lithium-ion battery series designed to meet NASA - National Aeronautics and Space Administration’s JSC 20793 safety standards!
These safety standards are specifically designed to ensure reliability and protection against failure when exposed to the extreme conditions of space. 🪐
Our advanced 18650 cells were selected for the K1S battery to demonstrate next-generation performance, safety, and resilience in orbital environments. 🛰️
We’re honored to support this milestone in a growing $6.35B space battery market, alongside other top-tier manufacturers. Together, we’re advancing safer, more efficient, and cost-effective energy solutions for space exploration. 🚀
Learn more about this upcoming mission in the press release below!
hashtag#tech hashtag#batterytech hashtag#space hashtag#NASA hashtag#futuretech hashtag#innovation hashtag#explore hashtag#AMPX
https://www.linkedin.com/posts/ampriustechnologies_kulr-signs-service-agreement-to-launch-kulr-activity-7282087902036013056-29tZ?utm_source=share&utm_medium=member_desktop
TradingCharts
2 semanas hace
KANG SUN
Powering the Future of Electric Mobility
https://www.linkedin.com/in/kang-sun-01775310/
Chief Executive Officer, Amprius Technologies Inc., Fremont, California [NYSE:AMPX] ▫️Chief Executive Officer, Amprius Inc., Fremont, California▫️Chairman, Berzelius Limited, Hong Kong,▫️Chairman and CEO, Amprius (Wuxi) Co. Ltd., Wuxi, China▫️Chairman and Chief Executive Officer, RayTracker Inc., Pasadena, California [acquired by NASDAQ:FSLR] ▫️President and Chief Operating Officer, JA Solar Co. Ltd., Shanghai, China NASDAQ:JASO ▫️Vice President and General Manager, Honeywell International Inc., Morristown, New Jersey, U.S.A. NASDAQ:HON ▫️Vice President of Technology, Oce N.V., Venlo, the Netherlands AMX:OCE.
whats the value of Honeywell International Inc., Morristown, New Jersey, U.S.A. [NASDAQ:HON]
As of the latest trading close, Honeywell International Inc. (NASDAQ: HON) is valued at $226.52. The stock has shown some volatility recently, fluctuating between $224.66 and $227.99. Honeywell's market capitalization stands at approximately $147.29 billion
TradingCharts
1 mes hace
KULR Signs Service Agreement to Launch KULR ONE Space Battery
December 17, 2024
https://www.kulrtechnology.com/kulr-signs-service-agreement-to-launch-kulr-one-space-battery/
Key highlights of the K1S rideshare mission include:
Integration of top cells from leading cell manufactures: The K1S variations will feature state-of-the-art 18650 cells delivered by top-tier original equipment manufacturers (OEMs), including LG, Samsung, Amprius, and MOLICEL.
timberwolf7
1 mes hace
Hope it works out for you, me, et al.
One caveat to be clear, they have a ways (TIME) to go...
and at this point, no idea what the 'justified' peak price could be IF
they are approved until sales, reimbursement prices, et al are announced.
My $3/sh is merely the result of what the market is likely to give it given their
development is a NEEDED product..
timberwolf7
1 mes hace
For those looking for something, check out TNXP:
-developed a drug to treat the PAIN from fibromyalgia
-ran 3 PH 3 trials, the 2nd one failed, but they say is was
only because it was run during the covid mess, and some dropped out
-there has been no drugs approved for fibro since around 2010 or so and
they are codeine based (think addiction)
-this one isn't codeine based
Where they are at:
-they submitted their New Drug Application in Oct
-there is a 60 day window in which the fda acts to accept or reject (do more)
the submission, its closing down (and maybe why the share price is moving as
momentum/bio even traders like to 'chase' binary decisions like this)
-my 1st target price is 50 cents if the NDA is accepted for consideration
-my target price if approved is $3
Concerns:
-never invested in a drug that treats PAIN before, so relying on the company to
be honest w/regard to the clinical trials
-will the 3 trials run satisfy the fda and the results be acceptable
-large share count, expect a reverse split down the road. But being in early and
the possibility of capturing some gains first? Helps mitigate the r/split effect.
Disclaimer: I do own shares at 17.5 cents because I trust the outcome of the clinical trials
and the only reason I am concerned with the 'robustness' of the trial design itself? I had another
one ATNM that I have followed for years, traded shares in, pass their PH 3 with flying colors.
Only to have the fda tell them they want them to run a new trial that (despite the fda accepting the trial
they ran in the first place) does more. Did not see it coming and the only good thing was, due to the
delays in another one I had shares in CRMD, I hadn't rotated a lot of that money over into ATNM. Saved
me from getting killed. So while I like TNXP, own a bunch of shares, I don't have as many as I would like
to.
just thought I would toss it out. As always, take your own look, do your own DD first before investing..
Good luck
timberwolf7
1 mes hace
Good question with the only right answer that we usually
can't give a good read on is, will it ever recover to where it just was
and then go higher. And because of my own lessons learned over the
years?
If I don't have confidence in what I think might happen, I usually hesitate
to take a position. And if I do take one (which is rare), my approach is to
take what it gives if a run takes place.
Part of my concern with how the market has changed since 2000 with the expansion
into online trading, the use of computer run ALGOs, things are happening too fast.
And too many moves in share price are the result not of fundamentals driving the share price,
but momentum based on hype, PR controlling things. And far too often, when one of
those moments develop, since its a 'false' run, ya just don't know when it will end, or how
far it will collapse the share price when it does. Until it has happened and is over.
Know someone who had recently bought ITRM at around $1.39 after its drug got approved. I told
him I didn't like it because of how 'limited' its market potential is due to the fda's labeling of
who and when it could be used. But then the share price started running up, he was happy
as he should be, but I recommended he be ready to take 'what it gave'. It peaked out
a couple of days ago around $2.90 and has collapsed hard over the last 2 days. I haven't
talked to him since this happened, so not sure if he 'took' the gains or if he is stil holding onto
the shares.
But in all honesty, while I expected it to peak out, and the momentum run it had was a nice one,
also had no clue as to how far it would then fall off.. So could only recommend taking what it
gave, and then see what happens next. Cause the fundamentals/outlook wasn't good enough
to justify a higher share price 'sticking'. And if it took off even higher, so be it. Just be happy
with the gains you did capture.
To close, its only in hindsight that we know how our decisions 'worked out'. But I am more inclined now
to take gains if I can't conservatively justify a higher share price going forward. Or I think something is
ahead of where it should be with the future 'cloudy/uncertain'.
Regístrate para interactuar en nuestros foros activos para discutir con inversores de ideas afines.
glenn1919
1 semana hace
aBeezlee
2 semanas hace
Hot Features
Premium
